Lessons from rheumatoid arthritis and inflammatory bowel disease: The importance of patient-centred outcomes in severe asthma

Abstract

Biologic therapies have transformed care for people with severe asthma, yet treatment response has traditionally been assessed using clinician-derived measures, including lung function, exacerbation rates, and oral corticosteroid use. These metrics, while clinically important, frequently fail to capture what matters most to patients: their ability to participate in daily life, maintain relationships, and sustain work and social roles. The publication of the Core Outcome Measures Set for Severe Asthma (COMSA) and the subsequent CompOsite iNdexes For Response in asthMa (CONFiRM) composite score mark a shift towards patient-centred measurement of treatment response in severe asthma. Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) travelled this path decades earlier. Both conditions adopted composite scoring tools, such as the Disease Activity Score-28 (DAS28) and the Mayo Score, that incorporated Patient-Reported Outcome Measures (PROMs) alongside objective markers. Initiatives like Outcome Measures in Rheumatology (OMERACT) in RA and Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) in IBD demonstrate that sustained, multidisciplinary collaboration between patients, clinicians, regulators, and industry can successfully embed PROMs into clinical trials and routine care. We argue that timely integration of health-related quality of life measures into clinical trials and practice requires electronic data collection, regulatory endorsement of PROMs as co-primary endpoints, and genuine patient partnership in research, beyond tokenism. By learning from parallel specialties, the asthma community can build a model of care that reflects what truly matters to those living with the disease.

Keywords

severe asthma / patient-reported outcomes / health-related quality of life / biologic therapy / composite outcome scores / COMSA

References

[1] Brusselle GG, Koppelman GH . Biologic Therapies for Severe Asthma. N Engl J Med. 2022; 386: 157-71.

[2] Sweeney J, Patterson CC, Menzies—Gow A, Niven RM, Mansur AH, Bucknall C, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross—sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016; 71: 339-46.

[3] Ainsworth B, Chatburn E, Bansal AT, Fulton O, Hamerlijnck D, Coleman C, et al. What bothers severe asthma patients most? A paired patient—clinician study across seven European countries. ERJ Open Res. 2023; 9: 00717—2022.

[4] Khaleva E, Rattu A, Brightling C, Bush A, Bossios A, Bourdin A, et al. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). Eur Respir J. 2023; 61: 2200606.

[5] Khaleva E, Brightling C, Eiwegger T, Altraja A, Bégin P, Blumchen K, et al. Patient—centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma. Eur Respir J. 2025; 65: 2400691.

[6] Lanario JW, Burns L . Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review. J Asthma Allergy. 2021; 14: 999-1010.

[7] Louis G, Voz B, Guillaume M, Kirkove D, Pétré B . The use of patient—reported outcome measures by healthcare professionals in specialized asthma management centers in French—speaking Belgium: A mixed—methods study. Clin Transl Allergy. 2023; 13: e12248.

[8] Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL . Modified disease activity scores that include twenty—eight—joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 2005; 38: 44-8.

[9] Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L . OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials. 2007; 8: 38.

[10] de Wit M, Abma T, Koelewijn—van Loon M, Collins S, Kirwan J . Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open. 2013; 3: e002241.

[11] Pincus T, Bergman MJ, Yazici Y . RAPID3—an index of physical function, pain, and global status as “vital signs” to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis. 2009; 67: 211-25.

[12] Ferguson S, Zemlicka L, Weber A, Halabi A, Arnason J, Bartels C, et al. Implementing RAPID—3 Using Electronic Patient Portal and Point of Care Entry. Arthritis Rheumatol. 2022.

[13] Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C—reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007; 66: 1221—6.

[14] Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E . DAS28—CRP and DAS28—ESR cut—offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open. 2017; 3: e000382.

[15] Schroeder KW, Tremaine WJ, Ilstrup DM . Coated Oral 5—Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. N Engl J Med. 1987; 317: 1625—9.

[16] Best WR, Becktel JM, Singleton JW, Kern F . Development of a Crohn’s Disease Activity Index. Gastroenterology. 1976; 70: 439-44.

[17] Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, et al. Development of the IBD disk: a visual self—administered tool for assessing disability in inflammatory bowel diseases. Inflamm Bowel Dis. 2017; 23: 333-40.

[18] Le Berre C, Flamant M, Bouguen G, Siproudhis L, Dewitte M, Dib N, et al. VALIDation of the IBD—Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study. J Crohn’s Colitis. 2020; 14: 1512—23.

[19] Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE—II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat—to—Target strategies in IBD. Gastroenterology. 2021; 160: 1570—83.

[20] Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, et al. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022; 20: 2619-27.e1.

[21] U.S. Food and Drug Administration . Rheumatoid Arthritis: Developing Drug Products for Treatment. Guidance for Industry. FDA; 2013.

[22] U.S. Food and Drug Administration . Ulcerative Colitis: Clinical Trial Endpoints. Guidance for Industry. FDA; 2016.

[23] Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. Fontana (WI): GINA; 2026.